<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id><journal-title-group><journal-title>Dialogues in Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1294-8322</issn><issn pub-type="epub">1958-5969</issn><publisher><publisher-name>Les Laboratoires Servier</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4826776</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease</article-title><trans-title-group xml:lang="es"><trans-title>Estrategias optogen&#x000e9;ticas para evaluar la funci&#x000f3;n estriatal en modelos animales de la Enfermedad de Parkinson</trans-title></trans-title-group><trans-title-group xml:lang="fr"><trans-title>L'optog&#x000e9;n&#x000e9;tique et son utilisation pour &#x000e9;valuer la fonction striatale dans des mod&#x000e8;les animaux de la maladie de Parkinson</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parker</surname><given-names>Krystal L.</given-names></name><degrees>PhD</degrees><xref ref-type="corresp" rid="COR1">*</xref><aff>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Youngcho</given-names></name><degrees>PhD</degrees><aff>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Alberico</surname><given-names>Stephanie L.</given-names></name><degrees>BS</degrees><aff>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Emmons</surname><given-names>Eric B.</given-names></name><degrees>BA</degrees><aff>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Narayanan</surname><given-names>Nandakumar S.</given-names></name><degrees>MD, PhD</degrees><aff>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</aff></contrib></contrib-group><author-notes><corresp id="COR1"><label>*</label>E-mail: <email>klparkr@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><volume>18</volume><issue>1</issue><fpage>99</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2016 Institut la Conf&#x000e9;rence Hippocrate - Servier Research Group</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Optogenetics refers to the ability to control cells that have been genetically modified to express light-sensitive ion channels. The introduction of optogenetic approaches has facilitated the dissection of neural circuits. Optogenetics allows for the precise stimulation and inhibition of specific sets of neurons and their projections with fine temporal specificity. These techniques are ideally suited to investigating neural circuitry underlying motor and cognitive dysfunction in animal models of human disease. Here, we focus on how optogenetics has been used over the last decade to probe striatal circuits that are involved in Parkinson disease, a neurodegenerative condition involving motor and cognitive abnormalities resulting from degeneration of midbrain dopaminergic neurons. The precise mechanisms underlying the striatal contribution to both cognitive and motor dysfunction in Parkinson disease are unknown. Although optogenetic approaches are somewhat removed from clinical use, insight from these studies can help identify novel therapeutic targets and may inspire new treatments for Parkinson disease. Elucidating how neuronal and behavioral functions are influenced and potentially rescued by optogenetic manipulation in animal models could prove to be translatable to humans. These insights can be used to guide future brain-stimulation approaches for motor and cognitive abnormalities in Parkinson disease and other neuropsychiatric diseases.</p></abstract><trans-abstract xml:lang="es"><p>La optogen&#x000e9;tica se refiere a la capacidad de controlar c&#x000e9;lulas que han sido modificadas gen&#x000e9;ticamente para expresar canales i&#x000f3;nicos sensibles a la luz. La introducci&#x000f3;n de las estrategias optogen&#x000e9;ticas ha facilitado la disecci&#x000f3;n de los circuitos neurales. La optogen&#x000e9;tica permite precisar la estimulaci&#x000f3;n e inhibici&#x000f3;n de conjuntos espec&#x000ed;ficos de neuronas y sus proyecciones con una alta especificidad temporal. Estas t&#x000e9;cnicas idealmente est&#x000e1;n adaptadas para investigar los circuitos neurales que subyacen a la disfunci&#x000f3;n motora y cognitiva en modelos animales de la enfermedad humana. Este art&#x000ed;culo se enfoca en c&#x000f3;mo se ha empleado la optogen&#x000e9;tica durante la &#x000fa;ltima d&#x000e9;cada para explorar los circuitos neurales que est&#x000e1;n involucrados en la Enfermedad de Parkinson, una condici&#x000f3;n neurodegenerativa que incluye alteraciones motoras y cognitivas resultantes de la degeneraci&#x000f3;n de neuronas dopamin&#x000e9;rgicas del mesenc&#x000e9;falo. Aunque las estrategias optogen&#x000e9;ticas est&#x000e1;n algo alejadas del empleo cl&#x000ed;nico, el conocimiento a partir de estos estudios puede ayudar a identificar nuevos blancos terap&#x000e9;uticos y puede inspirar nuevos tratamientos para la Enfermedad de Parkinson. El esclarecer c&#x000f3;mo las mediciones neurales y conductuales son influenciadas y potencialmente recuperadas por la manipulaci&#x000f3;n optogen&#x000e9;tica podr&#x000ed;a llegar a ser traducible a los humanos. Estos conocimientos pueden ser empleados para guiar futuras estrategias de estimulaci&#x000f3;n cerebral para anormalidades motoras y cognitivas en la Enfermedad de Parkinson y otras enfermedades neuropsiqui&#x000e1;tricas.</p></trans-abstract><trans-abstract xml:lang="fr"><p>L'optog&#x000e9;n&#x000e9;tique est une m&#x000e9;thode permettant de contr&#x000f4;ler des cellules qui ont &#x000e9;t&#x000e9; pr&#x000e9;alablement g&#x000e9;n&#x000e9;tiquement modifi&#x000e9;es pour exprimer des canaux ioniques sensibles &#x000e0; la lumi&#x000e8;re. Son utilisation a ouvert la voie &#x000e0; l'analyse des circuits neuronaux car elle permet la stimulation et l'inhibition pr&#x000e9;cises de groupes sp&#x000e9;cifiques de neurones et de leurs projections avec une excellente sp&#x000e9;cificit&#x000e9; temporale. Ces techniques sont parfaitement adapt&#x000e9;es &#x000e0; l'examen des circuits neuronaux sous-tendant une dysfonction motrice et cognitive dans des mod&#x000e8;les animaux de pathologies humaines. Cet article met l'accent sur la fa&#x000e7;on dont l'optog&#x000e9;n&#x000e9;tique a &#x000e9;t&#x000e9; utilis&#x000e9;e ces 10 derni&#x000e8;res ann&#x000e9;es pour examiner les circuits striataux impliqu&#x000e9;s dans la maladie de Parkinson, une maladie neurod&#x000e9;g&#x000e9;n&#x000e9;rative dont les troubles moteurs et cognitifs r&#x000e9;sultent d'une d&#x000e9;g&#x000e9;n&#x000e9;rescence des neurones dopaminergiques du m&#x000e9;senc&#x000e9;phale. Les m&#x000e9;canismes pr&#x000e9;cis sous-tendant la contribution du striatum au dysfonctionnement moteur et cognitif de la maladie de Parkinson sont encore m&#x000e9;connus. Bien que l'optog&#x000e9;n&#x000e9;tique soit quelque peu &#x000e9;loign&#x000e9;e de l'usage clinique, les connaissances issues de ces &#x000e9;tudes peuvent aider &#x000e0; identifier de nouvelles cibles th&#x000e9;rapeutiques et sugg&#x000e9;rer de nouveaux traitements pour la maladie de Parkinson. Une fois &#x000e9;lucid&#x000e9;s, les m&#x000e9;canismes par lesquels les manipulations optog&#x000e9;n&#x000e9;tiques peuvent influencer et potentiellement restaurer les fonctions neuronales et comportementales pourraient &#x000ea;tre transpos&#x000e9;s chez l'homme. Ces connaissances pourraient alors &#x000ea;tre utilis&#x000e9;es pour mener de futures strat&#x000e9;gies de stimulation c&#x000e9;r&#x000e9;brale dans les anomalies motrices et cognitives de la maladie de Parkinson et d'autres maladies neuropsychiatriques.</p></trans-abstract><kwd-group><kwd><italic>animal model</italic></kwd><kwd><italic>dopamine</italic></kwd><kwd><italic>optogenetics</italic></kwd><kwd><italic>Parkinson disease</italic></kwd><kwd><italic>striatum</italic></kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The advent of optogenetic technologies has advanced the field of neuroscience by allowing the manipulation of specific neuronal populations with millisecond resolution using light. Optogenetics allows researchers to stimulate or inhibit brain cells defined by a specific promoter and to specifically target a particular brain region. Opsins, or light-sensitive proteins, are genetically expressed in the neurons of a model organism and can then be activated with ~1-ms temporally precise delivery of specific wavelengths of light <italic><xref rid="DialoguesClinNeurosci-18-99-g001" ref-type="fig">Figure 1</xref></italic>.<sup><xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref></sup> Optogenetic viruses, constructs, and equipment are now readily available, making this technology accessible for various applications.</p><p>The first light-sensitive protein was isolated in the 1970s from <italic>Halobacterium halobium,</italic> though it took many years for its bioengineering potential to be realized.<sup><xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref3" ref-type="bibr">3</xref></sup> In 2003, initial work was published by Ernst Bamberg, describing the use of Channelrhodopsin-2 (ChR2) to drive neuronal activity with light.<sup><xref rid="ref4" ref-type="bibr">4</xref></sup> In a 2005 paper, Boyden et al from Karl Deisseroth's laboratory further characterized ChR2's potential for fast, precise, and dynamic stimulation of neurons and made significant improvements in the ease of genetic expression and efficacy.<sup><xref rid="ref5" ref-type="bibr">5</xref></sup> Furthermore, optogenetic stimulation has almost no measurable side effects for the host tissue, proving to be minimally invasive for use in vivo in mammals.<sup><xref rid="ref6" ref-type="bibr">6</xref></sup> Optogenetic proteins have also been engineered for the targeted inhibition of neuronal populations <italic>(Figure</italic>).The two primary inhibitory opsins are NpHR, a halorhodopsin, and Arch, an archaerhodopsin.<sup><xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref5" ref-type="bibr">5</xref></sup> NpHR, a chloride pump, requires constant light to move through its photocycle and has slower dynamics than Arch, a proton pump, which has more potent inactivation effects.<sup><xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref></sup>
</p><fig orientation="portrait" id="DialoguesClinNeurosci-18-99-g001" position="float"><label>Figure 1.</label><caption><title>Optogenetic tools for modulating membrane voltage potential. Stimulating the neurons expressing the nonselective cation channel Channelrhodopsin-2 (ChR2) using blue light immediately depolarizes the neuron and triggers an action potential. Sometimes it is desirable to inhibit neuronal signaling instead of triggering it. Light stimulation of halorhodopsin (NpHR), a chloride pump, hyperpolarizes neurons and inhibits spikes in response to yellow light. Recent variants (named eNpHR2.0 and eNpHR3.0) exhibit improved membrane targeting in mammalian cells and consequently, photocurrents. Light-driven proton pumps such as archaerhodopsin-3 (Arch), Mac, bacteriorhodopsin (eBR), and rhodopsin-3 (GtR3) can also be used to hyperpolarize neurons and block signaling. Ca<sub>2+</sub>, calcium; ChETA, channelrhodopsin-2 mutant E12ET; mV, millivolts; Na+, sodium; nm, nanometer; SFO, step-function opsin; VChR1, <italic>Volvox</italic>-derived channelrhodopsin-1. Reproduced from reference 2: Pastrana E. Optogenetics: controlling cell function with light. <italic>Nat Methods</italic>. 2011;8(1):24-25. Copyright &#x000a9; Nature America, Inc. 2011</title></caption><graphic xlink:href="DialoguesClinNeurosci-18-99-g001"/></fig><p>Genetic technology facilitates cell-type specificity for targeting optogenetic proteins to individual classes of neurons. Lentiviruses or the more commonly used adeno-associated viral (AAV) vectors can be used to express a given construct in all neurons, excitatory pyramidal neurons, inhibitory interneurons, astrocytes, or oligodendrocytes, depending on the genetic promoter used.<sup><xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref11" ref-type="bibr">11</xref>-<xref rid="ref14" ref-type="bibr">14</xref></sup> The use of transgenic Cre-recombinase mouse lines affords definitive cell-type specificity. In combination with Cre-dependent AAV vectors or transgenic mice, robust expression can be attained in a cell type restricted by a chosen Cre-driving promoter.<sup><xref rid="ref15" ref-type="bibr">15</xref></sup> This technique allows researchers to use various existing transgenic Cre mouse lines and to ask precise, directed questions that can be used to gather information about the actions of neuronal subclasses.<sup><xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref17" ref-type="bibr">17</xref></sup> Another advantage presented by optogenetic technologies is the ability to target not only a specific cellular class, but also modulate the projections of that cell type to a structure of interest. Optical cannulae can be implanted in downstream structures receiving projections from the injection location as a way to target only efferent projections <italic><xref rid="DialoguesClinNeurosci-18-99-g002" ref-type="fig">Figure 2</xref></italic>.<sup><xref rid="ref1" ref-type="bibr">1</xref>-<xref rid="ref20" ref-type="bibr">20</xref></sup>
</p><fig orientation="portrait" id="DialoguesClinNeurosci-18-99-g002" position="float"><label>Figure 2.</label><caption><title>Targeting optogenetic tools in vivo. <bold>(Top)</bold> Direct stimulation of neuronal cell bodies is achieved by injecting virus at the target region and then implanting a light-delivery device above the injected region. Even this simple experiment can provide specificity with viruses that will not transduce afferent axons and fibers of passage. Additional cell-type specificity is attained either by cell-type-specific promoters in the viral vector or via a recombinase-dependent virus, injected in a transgenic animal expressing a recombinase such as Cre in specific cells, leading to specific expression of the transgene only in defined cell types. <bold> (Bottom)</bold> Projection (axonal) targeting is achieved by viral injection at the region harboring cell bodies, followed by implantation of a light-delivery device above the target region containing neuronal processes from the virally transduced region; in this way, cell types are targeted by virtue of their projections. Reproduced from reference 19: Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. <italic>Nat Rev Neurosci</italic>. 2012;13(4):251-266. Copyright &#x000a9; Nature Publishing Group, 2012. Originally published in reference 20: Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron. 2011;71(1):9-34. Copyright &#x000a9; Elsevier, Inc. 2011</title></caption><graphic xlink:href="DialoguesClinNeurosci-18-99-g002"/></fig><p>Because of their versatility, the various optogenetic proteins and stimulation techniques present a rich tool-box for a multitude of research questions. For comprehensive reviews on the use of optogenetics for a wide range of applications, see Yizhar et al,<sup><xref rid="ref20" ref-type="bibr">20</xref></sup> Zhang et al,<sup><xref rid="ref21" ref-type="bibr">21</xref></sup> and Deisseroth.<sup><xref rid="ref1" ref-type="bibr">1</xref></sup> Manipulating neuronal activity with the high level of temporal and spatial precision, cell type specificity, and control that optogenetics allows has led to major advancements in our understanding of basic neural circuitry. Additionally, pairing these methods with multichannel and multisite neuronal recordings has the potential to reveal how these circuits are disrupted in neuro psychiatric diseases such as Parkinson disease (PD).</p></sec><sec><title>Parkinson disease neural circuitry and current treatments</title><p>PD is a neurodegenerative disorder characterized by the gradual death of midbrain dopaminergic neurons in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA).<sup><xref rid="ref22" ref-type="bibr">22</xref>-<xref rid="ref24" ref-type="bibr">24</xref></sup> The cardinal symptoms of PD in humans are resting tremor, muscle rigidity, and akinesia (difficulty in initiating movements)&#x02014;of note, PD can also lead to nonmotor symptoms.<sup><xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref26" ref-type="bibr">26</xref></sup> PD symptoms result from striatal dysfunction. The striatum integrates projections from the cortex and thalamus to promote action selection <italic><xref rid="DialoguesClinNeurosci-18-99-g003" ref-type="fig">Figure 3</xref></italic>.<sup><xref rid="ref27" ref-type="bibr">27</xref>-<xref rid="ref29" ref-type="bibr">29</xref></sup> It mainly consists of medium spiny neurons (MSNs) expressing two main types of dopamine receptors: D<sub>1</sub>-type and D<sub>2</sub>-type.<sup><xref rid="ref30" ref-type="bibr">30</xref>&#x0003e;-<xref rid="ref33" ref-type="bibr">33</xref></sup> These populations are expressed in two main output pathways: D<sub>1</sub> in the striatonigral &#x0201c;direct&#x0201d; pathway, and D<sub>2</sub> in the striatopallidal or &#x0201c;indirect&#x0201d; pathway.<sup><xref rid="ref31" ref-type="bibr">31</xref>,<xref rid="ref32" ref-type="bibr">32</xref></sup> The striatonigral pathway directly inhibits the globus pallidus interna (Gpi) and substantia nigra pars reticulata (SNr). The striatopallidal pathway indirectly excites the GPi/SNr via disinhibition <italic>(Figure</italic> 3).<sup><xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref34" ref-type="bibr">34</xref></sup> The striatonigral (direct) pathway has been speculated to promote motor actions, whereas the striatopallidal (indirect) pathway suppresses actions. Imbalances between neural activities in the direct and indirect pathways in the basal ganglia caused by a loss of dopaminergic input result in profound motor deficits among patients with PD.<sup><xref rid="ref35" ref-type="bibr">35</xref>,<xref rid="ref36" ref-type="bibr">36</xref></sup>
</p><fig orientation="portrait" id="DialoguesClinNeurosci-18-99-g003" position="float"><label>Figure 3.</label><caption><title>In Parkinson disease, dopamine arising from the substantia nigra pars compacta is thought to activate D1-expressing striatal medium spiny neurons of the direct pathway (red lines) and to inhibit D2-expressing striatal neurons of the indirect pathway (blue lines). The output nuclei globus pallidus interna and substantia nigra pars reticulata project to the thalamus, which in turn sends efferents that complete the cortico-basal ganglia-thalamo-cortical loop. In Parkinson disease, degeneration of nigral neurons reduces dopamine-receptor stimulation in striatal medium spiny neurons. The imbalance between direct and indirect pathways results in abnormal activation of output nuclei and overinhibition of thalamic neurons projecting to the cortex. DA, dopamine; GPe, globus pallidus externa; GPi, globus pallidus interna; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus. Reproduced from reference 29: Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. <italic>Nat Neurosci</italic>. 2014;17(8):1022-1030. Copyright &#x000a9; Nature Publishing Group, 2014</title></caption><graphic xlink:href="DialoguesClinNeurosci-18-99-g003"/></fig></sec><sec><title>Optogenetics to probe striatal circuits and motor symptoms in animal models of PD</title><p>In animal models of PD, optogenetic approaches have been applied to answer a variety of fundamental research questions. There are two primary toxin-based animal models of PD, both of which are induced by toxic pharmacological lesion. The first involves a 6-hydroxydopamine (6-OHDA) injection into the substantia nigra, medial forebrain bundle (MFB), or striatum. The second requires repeatedly administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intraperitoneally.<sup><xref rid="ref37" ref-type="bibr">37</xref>-<xref rid="ref40" ref-type="bibr">40</xref></sup> Although 6-OHDA and MPTP animal models do not replicate the progressive loss of dopaminergic neurons, they model catecholamine dysfunction in PD. Other models involve &#x003b1;-synuclein overexpression or mutations; to our knowledge, optogenetics has not been explored in these models.<sup><xref rid="ref41" ref-type="bibr">41</xref>-<xref rid="ref43" ref-type="bibr">43</xref></sup>
</p><p>Optogenetics has provided details of striatal MSNs, interneurons, and afferents that could have implications for PD and other neuropsychiatric diseases (for complete review, see ref 44). As a result of the efficacy of subthalamic nucleus (STN) deep brain stimulation (DBS) on the motor symptoms of PD, Gradinaru et al<sup><xref rid="ref12" ref-type="bibr">12</xref></sup> investigated STN optogenetic inhibition and excitation as a method to mimic the effects of DBS in animals with 6-OHDA injections in the MFB <italic><xref rid="DialoguesClinNeurosci-18-99-g004" ref-type="fig">Figure 4</xref></italic>
<sup><xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref19" ref-type="bibr">19</xref>,<xref rid="ref45" ref-type="bibr">45</xref></sup> While optogenetic excitation and inhibition of STN neurons had no effect, high-frequency stimulation of afferent fibers projecting from the motor cortex to the STN ameliorated motor symptoms. It is important to note that infusions of muscimol and lidocaine in the STN have been demonstrated to relieve some PD symptoms in monkeys treated with MPTP<sup><xref rid="ref46" ref-type="bibr">46</xref></sup> Changes in STN activity following stimulation could influence downstream structures, including the striatum. These results illustrate how optogenetics can be used to precisely define neural circuitry and describe the influence of stimulation and inhibition on behavioral measures.</p><fig orientation="portrait" id="DialoguesClinNeurosci-18-99-g004" position="float"><label>Figure 4.</label><caption><title>A schematic diagram <bold>(top panel)</bold> shows key neural projections that are involved in parkinsonian behavior and treatment. Data in the <bold>bottom left panel</bold> are from a study that used a constitutively expressing ChR2 mouse line (Thy1::ChR2) to identify a mechanistic explanation for the therapeutic effects of deep brain stimulation. By illuminating and recording in the subthalamic nucleus, this paper showed that afferent fibers entering the subthalamic nucleus, rather than local cell bodies themselves, are likely to be the direct target of deep brain stimulation in the correction of parkinsonian motor activity. High-frequency stimulation of the afferent fibers into subthalamic nucleus potently silenced the structure as shown and reversibly abolished the parkinsonian symptoms. By contrast, low-frequency stimulation of the afferents simply added spikes on top of endogenous spikes and worsened parkinsonian symptoms.<sup><xref rid="ref12" ref-type="bibr">12</xref></sup> Data in the bottom right panel are from a study that used a Cre-AAV to selectively express ChR2 in either D1 dopamine receptor (D1R)::Cre or D2 dopamine receptor (D2R)::Cre mice to examine the differential contributions of the direct and indirect pathways with respect to motor output. Activation of D1R-expressing neurons silenced local basal ganglia activity and increased ambulation, whereas activation of D2R-expressing neurons increased this activity and enhanced immobile or bradykinetic (slow) behavior.45 Black bars indicate the duration of illumination. AAV, adeno-associated viral; ChR2, Channelrhodopsin-2; HFS, high-frequency stimulation; LFS, low-frequency stimulation; M1, primary motor cortex; &#x003bc;V, microvolts; D1, D1-type dopamine receptor; D2, D2-type dopamine receptor; GABA, &#x003b3;-aminobutyric acid; GP, globus pallidus; Hz, hertz; ms, milliseconds; s, seconds; SNr, substantia nigra pars reticulata; STN, subthalamic nuclus. Reproduced from reference 19: Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. <italic>Nat Rev Neurosci</italic>. 2012;13(4):251-266. &#x000a9; 2012, Nature Publishing Group. Bottom left image group originally published in reference 12: Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. <italic>Science</italic>. 2009;324(5925):354-359. &#x000a9; 2009, American Association for the Advancement of Science. Bottom right image group originally published in reference 45: Kravitz AV, Freeze BS, Parker PRL, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. <italic>Nature</italic>. 2010; 466(7306): 622-626. Copyright &#x000a9; Nature Publishing Group, 2010</title></caption><graphic xlink:href="DialoguesClinNeurosci-18-99-g004"/></fig><p>As previously described, it is thought that hyperactivity in the indirect pathway and insufficient activity in the direct pathways contribute to the motor symptoms of PD.<sup><xref rid="ref35" ref-type="bibr">35</xref></sup> To investigate this hypothesis, Kravitz et al<sup><xref rid="ref45" ref-type="bibr">45</xref></sup> used optogenetics to selectively probe these pathways in mice expressing D<sub>1</sub>-Cre or D<sub>2</sub>-Cre recombinasedependent ChR2 in MSNs. They found that bilateral stimulation of the D<sub>2</sub> neurons of the indirect pathway induced freezing and bradykinesia and decreased locomotion, whereas stimulation of the D<sub>1</sub> neurons of the direct pathway reduced freezing and increased locomotion. Additionally, they reported that optogenetic stimulation of the direct pathway rescued motor abnormalities induced by 6-OHDA lesions in the MFB (Figure 4). These data indicate the importance of the opposing influences of the direct and indirect pathways and indicate potential therapeutic strategies to ameliorate the motor deficits associated with PD.<sup><xref rid="ref45" ref-type="bibr">45</xref></sup>
</p><p>Optogenetics has also been used to probe the mechanisms underlying the efficacy of grafting human pluripotent stem cell-derived dopaminergic neurons in disease models. Animals with striatal 6-OHDA lesions exhibit motor impairments that are robustly reversed following engraftment of dopaminergic neurons in the lesioned area.<sup><xref rid="ref47" ref-type="bibr">47</xref></sup> To probe the mechanisms underlying the efficacy of this effect, Steinbeck et al<sup><xref rid="ref48" ref-type="bibr">48</xref></sup> optogenetically inhibited engrafted dopamine stem cells after motor recovery. They report that inhibiting dopamine neurons resulted in the reappearance of motor deficits, indicating the essential role of dopaminergic neurons at the lesion site.</p><p>The studies described here provide evidence for the importance of optogenetic exploration of striatal function in animal models of PD. These results could inform the design of novel drug- and stimulation-based therapies to rescue dopaminergic dysfunction and motor symptoms in PD.</p></sec><sec><title>Optogenics to probe neural circuitry and cognitive dysfunction in animal models of PD</title><p>In addition to the characteristic motor symptoms, non-motor symptoms are also present in PD including depression, psychosis, and cognitive dysfunction.<sup><xref rid="ref49" ref-type="bibr">49</xref></sup> Cognitive impairment is a serious component of PD for many patients. Though initially controversial, cognitive deficits are now an integral part of PD symptomatology. These cognitive symptoms can be diverse, including visuospatial dysfunction, working-memory deficits, and executive dysfunction.<sup><xref rid="ref50" ref-type="bibr">50</xref></sup> Despite its prevalence, the underlying basis of cognitive dysfunction in PD is poorly understood. Whereas treatments exist that successfully alleviate motor symptoms of PD, their cognitive benefits are not established.<sup><xref rid="ref51" ref-type="bibr">51</xref>-<xref rid="ref55" ref-type="bibr">55</xref></sup>
</p><p>Cognitive dysfunction in PD patients may involve the prefrontal cortex, a key input structure to the striatum.<sup><xref rid="ref56" ref-type="bibr">56</xref>-<xref rid="ref61" ref-type="bibr">61</xref></sup> Frontostriatal circuits are the primary neural pathways responsible for cognitive dysfunction in PD. The frontal cortex receives dopaminergic projections from dopaminergic neurons in the VTA. Dopaminergic neurons in the VTA also die during PD and therefore could play a role in disease-related cognitive abnormalities.<sup><xref rid="ref22" ref-type="bibr">22</xref></sup> Given the critical role of the dopaminergic system in the development of PD, its significance in cognitive symptoms of PD has also been studied.<sup><xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref63" ref-type="bibr">63</xref></sup>
</p><p>As described earlier in this review, animal models are a critical component of PD research. However, the relevance of animal models is less obvious when dealing with complicated internal processes like &#x0201c;cognitive dysfunction.&#x0201d; When trying to approach cognitive deficits of PD in an animal model, it is essential to find a behavioral assay that is simple, relies on the structures involved in the disease, and is translatable to human patients. Temporal processing tasks meet these criteria. Interval-timing tasks require subjects to make a motor estimation of the passage of an interval of time. Interval timing can be studied in both rodents and humans.<sup><xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref65" ref-type="bibr">65</xref></sup> Tasks that rely on time estimation are known to rely on dopaminergic systems.<sup><xref rid="ref66" ref-type="bibr">66</xref>-<xref rid="ref70" ref-type="bibr">70</xref></sup> Our group has shown that interval-timing tasks are impaired in PD and in rodents administered 6-OHDA injections in the VTA or in the frontal cortex.<sup><xref rid="ref71" ref-type="bibr">71</xref></sup> Specifically, we found that disrupting dopamine synthesis also impaired interval timing. We used optogenetics to specifically implicate prefrontal <italic>D<sub>1</sub></italic> dopamine receptors and demonstrated that stimulating prefrontal D<sub>1</sub> neurons could enhance performance of timing tasks.<sup><xref rid="ref72" ref-type="bibr">72</xref></sup> Additionally, PD patients and rodent PD models had diminished frontal, low-frequency, cue-related activity and single-neuron ramping activity, indicating conserved mechanisms for timing and cognitive function.<sup><xref rid="ref73" ref-type="bibr">73</xref></sup>
</p><p>Optogenetics provides a novel way to probe frontostriatal interactions in animals performing the interval-timing task and can be tailored specifically to D<sub>1</sub> dopamine receptors using Cre-dependent expression of ChR2 or other opsins. These techniques can be used in animal models of PD with depleted D<sub>1</sub> dopamine to try to ameliorate aberrant frontal and striatal neuronal activity and rescue performance on behavioral tasks. The same techniques could be used to probe cognitive flexibility and frontostriatal circuitry in other paradigms including reversal learning, attentional set-shifting, and task switching. These tasks are impaired in PD and can all be explored in animal models.<sup><xref rid="ref74" ref-type="bibr">74</xref></sup> Elucidating the neural mechanisms of cognitive impairment in neuropsychiatric disease may identify novel sites for DBS or transcranial magnetic stimulation in PD, schizophrenia, and other neuropsychiatric diseases that share dysfunctional D<sub>1</sub>-dopamine and striatal abnormalities. <sup><xref rid="ref75" ref-type="bibr">75</xref>&#x0003e;-<xref rid="ref78" ref-type="bibr">78</xref></sup> Results from these proposed studies have the potential to illuminate the neural mechanisms of cognitive impairment and help identify novel biomarkers and novel therapeutic targets for the D<sub>1</sub> dopamine system.</p></sec><sec><title>Future directions</title><p>This review summarizes the powerful contribution that optogenetics has made to our understanding of striatal circuitry, abnormalities in PD, and the potential for striatal modulation as a novel therapeutic target in PD. Yet, it is clear that if we aim to inspire new treatments for PD, there is a great need for further optogenetic exploration of striatal circuitry and function in animal models. Looking forward, optogenetics can be used to pave the way for emerging technologies to adaptively stimulate brain circuitry in diseases of impaired motor and cognitive function. If we can map specific neuronal abnormalities and show that optogenetic stimulation or inhibition successfully rescues motor and/or cognitive impairments in animal models of PD, an online, closed-loop design could be used to stimulate aberrant circuits. In patients with PD, cognitive and motor function could be restored using concomitant electroencephalography to detect neural abnormalities and deep brain or transcranial stimulation to adaptively rescue specific patterns of neuronal activity.<sup><xref rid="ref79" ref-type="bibr">79</xref></sup>
</p></sec></body><back><ref-list><title>REFERENCES
</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Optogenetics.</article-title><source><italic>Nat Methods.</italic></source><year>2011</year><volume>8</volume><issue>1</issue><fpage>26</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">21191368</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastrana</surname><given-names>E.</given-names></name></person-group><article-title>Optogenetics: controlling cell function with light.</article-title><source><italic>Nat Methods</italic></source><year>2011</year><volume>8</volume><issue>1</issue><fpage>24</fpage><lpage>25</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oesterhelt</surname><given-names>D.</given-names></name><name><surname>Stoeckenius</surname><given-names>W.</given-names></name></person-group><article-title>Functions of a new photoreceptor membrane.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>1973</year><volume>70</volume><issue>10</issue><fpage>2853</fpage><lpage>2857</lpage><pub-id pub-id-type="pmid">4517939</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagel</surname><given-names>G.</given-names></name><name><surname>Szellas</surname><given-names>T.</given-names></name><name><surname>Huhn</surname><given-names>W.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Channelrhodopsin-2, a directly light-gated cation-selective membrane channel.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2003</year><volume>100</volume><issue>24</issue><fpage>13940</fpage><lpage>13945</lpage><pub-id pub-id-type="pmid">14615590</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyden</surname><given-names>ES.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Bamberg</surname><given-names>E.</given-names></name><name><surname>Nagel</surname><given-names>G.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Millisecond-timescale, genetically targeted optical control of neural activity.</article-title><source><italic> Nat Neurosci.</italic></source><year>2005</year><volume>8</volume><issue>9</issue><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">16116447</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aravanis</surname><given-names>AM.</given-names></name><name><surname>Wang</surname><given-names>LP.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>et al</surname></name></person-group><article-title>An optical neural interface: in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology</article-title><source><italic>J Neural Eng</italic></source><year>2001</year><volume>4</volume><issue>3</issue><fpage>S143</fpage><pub-id pub-id-type="pmid">17873414</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>BY.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Dobry</surname><given-names>AS.</given-names></name><name><surname>et al</surname></name></person-group><article-title>High-performance genetically targetable optical neural silencing by light-driven proton pumps.</article-title><source><italic>Nature.</italic></source><year>2010</year><volume>463</volume><issue>7277</issue><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">20054397</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradinaru</surname><given-names>V.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Ramakrishnan</surname><given-names>C.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Molecular and cellular approaches for diversifying and extending optogenetics.</article-title><source><italic>Cell.</italic></source><year>2010</year><volume>141</volume><issue>1</issue><fpage>154</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">20303157</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>A.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name></person-group><article-title>An optogenetic application of proton pump ArchT to <italic>C. elegans</italic> cells.</article-title><source><italic>Neurosci Res.</italic></source><year>2013</year><volume>75</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">23044183</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>IB.</given-names></name><name><surname>Lin</surname><given-names>SC.</given-names></name><name><surname>Brodsky</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Cholinergic interneurons control local circuit activity and cocaine conditioning.</article-title><source><italic>Science.</italic></source><year>2010</year><volume>330</volume><issue>6011</issue><fpage>1677</fpage><lpage>1681</lpage><pub-id pub-id-type="pmid">21164015</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diester</surname><given-names>I.</given-names></name><name><surname>Kaufman</surname><given-names>MT.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>An optogenetic toolbox designed for primates.</article-title><source><italic>Nat Neurosci.</italic></source><year>2011</year><volume>14</volume><issue>3</issue><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">21278729</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradinaru</surname><given-names>V.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>KR.</given-names></name><name><surname>Henderson</surname><given-names>JM.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Optical deconstruction of parkinsonian neural circuitry.</article-title><source><italic>Science.</italic></source><year>2009</year><volume>324</volume><issue>5925</issue><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">19299587</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawlor</surname><given-names>PA.</given-names></name><name><surname>Bland</surname><given-names>RJ.</given-names></name><name><surname>Mouravlev</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>D.</given-names></name><name><surname>During</surname><given-names>MJ.</given-names></name></person-group><article-title>Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.</article-title><source><italic>Mol Ther.</italic></source><year>2009</year><volume>17</volume><issue>10</issue><fpage>1692</fpage><lpage>1702</lpage><pub-id pub-id-type="pmid">19638961</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathanson</surname><given-names>JL.</given-names></name><name><surname>Jappelli</surname><given-names>R.</given-names></name><name><surname>Scheeff</surname><given-names>ED.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Short promoters in viral vectors drive selective expression in mammalian inhibitory neurons, but do not restrict activity to specific inhibitory cell-types.</article-title><source><italic>Front Neural Circuits.</italic></source><year>2009</year><volume>3</volume><fpage>19</fpage><pub-id pub-id-type="pmid">19949461</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atasoy</surname><given-names>D.</given-names></name><name><surname>Aponte</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>HH.</given-names></name><name><surname>Sternson</surname><given-names>SM.</given-names></name></person-group><article-title>A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping.</article-title><source><italic>J Neurosci.</italic></source><year>2008</year><volume>28</volume><issue>28</issue><fpage>7025</fpage><lpage>7030</lpage><pub-id pub-id-type="pmid">18614669</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardin</surname><given-names>JA.</given-names></name></person-group><article-title>Dissecting local circuits in vivo: integrated optogenetic and electrophysiology approaches for exploring inhibitory regulation of cortical activity.</article-title><source><italic>J Physiol Paris.</italic></source><year>2012</year><volume>106</volume><issue>3-4</issue><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">21958624</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardin</surname><given-names>JA.</given-names></name><name><surname>Carlen</surname><given-names>M.</given-names></name><name><surname>Meletis</surname><given-names>K.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Targeted optogenetic stimulation and recording of neurons in vivo using cell-type-specific expression of Channelrhodopsin-2.</article-title><source><italic>Nat Protoc.</italic></source><year>2010</year><volume>5</volume><issue>2</issue><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">20134425</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hira</surname><given-names>R.</given-names></name><name><surname>Ohkubo</surname><given-names>F.</given-names></name><name><surname>Tanaka</surname><given-names>YR.</given-names></name><name><surname>et al</surname></name></person-group><article-title>In vivo optogenetic tracing of functional corticocortical connections between motor forelimb areas.</article-title><source><italic>Front Neural Circuits.</italic></source><year>2013</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="pmid">23554588</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>KM.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Optogenetic investigation of neural circuits underlying brain disease in animal models.</article-title><source><italic>Nat Rev Neurosci.</italic></source><year>2012</year><volume>13</volume><issue>4</issue><fpage>251</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">22430017</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yizhar</surname><given-names>O.</given-names></name><name><surname>Fenno</surname><given-names>LE.</given-names></name><name><surname>Davidson</surname><given-names>TJ.</given-names></name><name><surname>Mogri</surname><given-names>M.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Optogenetics in neural systems.</article-title><source><italic>Neuron.</italic></source><year>2011</year><volume>71</volume><issue>1</issue><fpage>9</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">21745635</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Aravanis</surname><given-names>AM.</given-names></name><name><surname>Adamantidis</surname><given-names>A.</given-names></name><name><surname>de Lecea</surname><given-names>L.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Circuit-breakers: optical technologies for probing neural signals and systems.</article-title><source><italic>Nat Rev Neurosci.</italic></source><year>2007</year><volume>8</volume><issue>8</issue><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">17643087</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberico</surname><given-names>SL.</given-names></name><name><surname>Cassell</surname><given-names>MD.</given-names></name><name><surname>Narayanan</surname><given-names>NS.</given-names></name></person-group><article-title>The vulnerable ventral tegmental area in Parkinson's disease.</article-title><source><italic>Basal Ganglia.</italic></source><year>2015</year><volume>5</volume><issue>2-3</issue><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">26251824</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damier</surname><given-names>P.</given-names></name><name><surname>Hirsch</surname><given-names>EC.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name><name><surname>Graybiel</surname><given-names>AM.</given-names></name></person-group><article-title>The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</article-title><source><italic>Brain.</italic></source><year>1999</year><volume>122</volume><issue>8</issue><fpage>1437</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">10430830</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zold</surname><given-names>CL.</given-names></name><name><surname>Kasanetz</surname><given-names>F.</given-names></name><name><surname>Pomata</surname><given-names>PE.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Striatal gating through up states and oscillations in the basal ganglia: implications for Parkinson's disease.</article-title><source><italic>J Physiol Paris.</italic></source><year>2012</year><volume>106</volume><issue>1-2</issue><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">21767642</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR.</given-names></name><name><surname>Healy</surname><given-names>DG.</given-names></name><name><surname>Schapira</surname><given-names>AH.</given-names></name></person-group><article-title>Non-motor symptoms of Parkinson's disease: diagnosis and management.</article-title><source><italic>Lancet Neurol.</italic></source><year>2006</year><volume>5</volume><issue>3</issue><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">16488379</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>KL.</given-names></name><name><surname>Lamichhane</surname><given-names>D.</given-names></name><name><surname>Caetano</surname><given-names>MS.</given-names></name><name><surname>Narayanan</surname><given-names>NS.</given-names></name></person-group><article-title>Executive dysfunction in Parkinson's disease and timing deficits.</article-title><source><italic>Front Integr Neurosci.</italic></source><year>2013</year><volume>7</volume><fpage>75</fpage><pub-id pub-id-type="pmid">24198770</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolam</surname><given-names>JP.</given-names></name><name><surname>Hanley</surname><given-names>JJ.</given-names></name><name><surname>Booth</surname><given-names>PA.</given-names></name><name><surname>Bevan</surname><given-names>MD.</given-names></name></person-group><article-title>Synaptic organisation of the basal ganglia</article-title><source><italic>J Anat.</italic></source><year>2000</year><volume>196</volume><issue>Pt 4</issue><fpage>527</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">10923985</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freemon</surname><given-names>FR.</given-names></name></person-group><article-title>The synaptic organisation of the brain.</article-title><source><italic>JAMA.</italic></source><year>1980</year><volume>243</volume><issue>18</issue><fpage>1850</fpage><lpage>1850</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>P.</given-names></name><name><surname>Picconi</surname><given-names>B.</given-names></name><name><surname>Tozzi</surname><given-names>A.</given-names></name><name><surname>Ghiglieri</surname><given-names>V.</given-names></name><name><surname>Di Filippo</surname><given-names>M.</given-names></name></person-group><article-title>Direct and indirect pathways of basal ganglia: a critical reappraisal.</article-title><source><italic>Nat Neurosci.</italic></source><year>2014</year><volume>17</volume><issue>8</issue><fpage>1022</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">25065439</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerfen</surname><given-names>CR.</given-names></name></person-group><article-title>Molecular effects of dopamine on striatal-projection pathways.</article-title><source><italic>Trends Neurosci.</italic></source><year>2000</year><volume>23</volume><fpage>S64</fpage><lpage>S70</lpage><pub-id pub-id-type="pmid">11052222</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname><given-names>AC.</given-names></name></person-group><article-title>Physiology and pharmacology of striatal neurons.</article-title><source><italic>Annu Rev Neurosci.</italic></source><year>2009</year><volume>32</volume><fpage>127</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">19400717</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>Y.</given-names></name><name><surname>Bevan</surname><given-names>MD.</given-names></name><name><surname>Shink</surname><given-names>E.</given-names></name><name><surname>Bolam</surname><given-names>JP.</given-names></name></person-group><article-title>Microcircuitry of the direct and indirect pathways of the basal ganglia.</article-title><source><italic>Neuroscience.</italic></source><year>1998</year><volume>86</volume><issue>2</issue><fpage>353</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">9881853</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surmeier</surname><given-names>DJ.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Day</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name></person-group><article-title>D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons.</article-title><source><italic>Trends Neurosci.</italic></source><year>2007</year><volume>30</volume><issue>5</issue><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">17408758</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeso</surname><given-names>JA.</given-names></name><name><surname>Rodriguez-Oroz</surname><given-names>MC.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Pathophysiology of the basal ganglia in Parkinson's disease. doi:http://dx.doi.org/10.1016/51471-1931(00)00028-8</article-title><source><italic>Trends Neurosci.</italic></source><year>2000</year><volume>23</volume><issue>suppl 1</issue><fpage>S8</fpage><lpage>S19</lpage><pub-id pub-id-type="pmid">11052215</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albin</surname><given-names>RL.</given-names></name><name><surname>Young</surname><given-names>AB.</given-names></name><name><surname>Penney</surname><given-names>JB.</given-names></name></person-group><article-title>The functional anatomy of basal ganglia disorders.</article-title><source><italic>Trends Neurosci.</italic></source><year>1989</year><volume>12</volume><issue>10</issue><fpage>366</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">2479133</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graybiel</surname><given-names>AM.</given-names></name><name><surname>Aosaki</surname><given-names>T.</given-names></name><name><surname>Flaherty</surname><given-names>AW.</given-names></name><name><surname>Kimura</surname><given-names>M.</given-names></name></person-group><article-title>The basal ganglia and adaptive motor control.</article-title><source><italic>Science</italic></source><year>1994</year><volume>265</volume><issue>5180</issue><fpage>1826</fpage><lpage>1831</lpage><pub-id pub-id-type="pmid">8091209</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahn</surname><given-names>S.</given-names></name><name><surname>Marsden</surname><given-names>CD.</given-names></name></person-group><article-title>World Congress of Neurology Carnforth, Lanes, UK: Park Ridge, NJ, USA: Parthenon Pub Group: 1990. http://catalog.hathitrust.org/Record/002235224.</article-title><source><italic>The Assessment and Therapy of Parkinsonism: The Proceedings of a Symposium Held at the XlVth World Congress of Neurology, New Delhi, October 1989.</italic></source><lpage>38</lpage></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaakkola</surname><given-names>S.</given-names></name><name><surname>Ter&#x000e4;v&#x000e4;inen</surname><given-names>H.</given-names></name></person-group><article-title>Animal models of parkinsonism.</article-title><source><italic>Pharmacol Toxicol.</italic></source><year>1990</year><volume>67</volume><issue>2</issue><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">2123984</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schober</surname><given-names>A.</given-names></name></person-group><article-title>Classic toxin-induced animal models of Parkinson's disease: 6-OHD A and MPTP.</article-title><source><italic>Cell Tissue Res.</italic></source><year>2004</year><volume>318</volume><issue>1</issue><fpage>21 5</fpage><lpage>224</lpage></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ungerstedt</surname><given-names>U.</given-names></name><name><surname>Arbuthnott</surname><given-names>GW.</given-names></name></person-group><article-title>Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.</article-title><source><italic>Brain Res.</italic></source><year>1970</year><volume>24</volume><issue>3</issue><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">5494536</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesselet</surname><given-names>MF.</given-names></name><name><surname>Fleming</surname><given-names>S.</given-names></name><name><surname>Mortazavi</surname><given-names>F.</given-names></name><name><surname>Meurers</surname><given-names>B.</given-names></name></person-group><article-title>Strengths and limitations of genetic mouse models of Parkinson's disease.</article-title><source><italic>Parkinsonism Relat Disord.</italic></source><year>2008</year><volume>14</volume><issue>supp 12</issue><fpage>S84</fpage><lpage>S87</lpage><pub-id pub-id-type="pmid">18585084</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MK.</given-names></name><name><surname>Stirling</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Human &#x003b1;-synuclein-harboring familial Parkinson's disease-linked Ala- 53 &#x0201d; Thr mutation causes neurodegenerative disease with &#x003b1;-synuclein aggregation in transgenic mice.</article-title><source><italic>Proc Natl Acad Sci USA.</italic></source><year>2002</year><volume>99</volume><issue>13</issue><fpage>8968</fpage><lpage>8973</lpage><pub-id pub-id-type="pmid">12084935</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decressac</surname><given-names>M.</given-names></name><name><surname>Kadkhodaei</surname><given-names>B.</given-names></name><name><surname>Mattsson</surname><given-names>B.</given-names></name><name><surname>Laguna</surname><given-names>A.</given-names></name><name><surname>Perlmann</surname><given-names>T.</given-names></name><name><surname>Bj&#x000f6;rklund</surname><given-names>A.</given-names></name></person-group><article-title>&#x003b1;-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.</article-title><source><italic>Sci TransI Med.</italic></source><year>2012</year><volume>4</volume><issue>163</issue><fpage>163ra156</fpage></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenz</surname><given-names>JD.</given-names></name><name><surname>Lobo</surname><given-names>MK.</given-names></name></person-group><article-title>Optogenetic insights into striatal function and behavior.</article-title><source><italic>Behav Brain Res.</italic></source><year>2013</year><volume>255</volume><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">23628212</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kravitz</surname><given-names>AV.</given-names></name><name><surname>Freeze</surname><given-names>BS.</given-names></name><name><surname>Parker</surname><given-names>PRL.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.</article-title><source><italic>Nature.</italic></source><year>2010</year><volume>466</volume><issue>7306</issue><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">20613723</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>R.</given-names></name><name><surname>Lang</surname><given-names>AE.</given-names></name><name><surname>Dostrovsky</surname><given-names>JO.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms.</article-title><source><italic>Brain.</italic></source><year>2001</year><volume>124</volume><issue>Pt 10</issue><fpage>2105</fpage><lpage>2118</lpage><pub-id pub-id-type="pmid">11571226</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriks</surname><given-names>S.</given-names></name><name><surname>Shim</surname><given-names>JW.</given-names></name><name><surname>Piao</surname><given-names>J.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.</article-title><source><italic>Nature.</italic></source><year>2011</year><volume>480</volume><issue>7378</issue><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">22056989</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbeck</surname><given-names>JA.</given-names></name><name><surname>Choi</surname><given-names>SJ.</given-names></name><name><surname>Mrejeru</surname><given-names>A.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model.</article-title><source><italic>Nat Biotechnol.</italic></source><year>2015</year><volume>33</volume><issue>2</issue><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">25580598</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR.</given-names></name><name><surname>Schapira</surname><given-names>AH.</given-names></name></person-group><article-title>Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.</article-title><source><italic>Lancet Neurol.</italic></source><year>2009</year><volume>8</volume><issue>5</issue><fpage>464</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">19375664</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Pillon</surname><given-names>B.</given-names></name></person-group><article-title>Cognitive deficits in Parkinson's disease.</article-title><source><italic>J Neurol.</italic></source><year>1997</year><volume>244</volume><issue>1</issue><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9007738</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deuschl</surname><given-names>G.</given-names></name><name><surname>Schade-Brittinger</surname><given-names>C.</given-names></name><name><surname>Krack</surname><given-names>P.</given-names></name><name><surname>et al</surname></name></person-group><article-title>A randomized trial of deep-brain stimulation for Parkinson's disease.</article-title><source><italic>N Engl J Med.</italic></source><year>2006</year><volume>355</volume><issue>9</issue><fpage>896</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">16943402</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>CE.</given-names></name><name><surname>Borod</surname><given-names>JC.</given-names></name><name><surname>Brin</surname><given-names>MF.</given-names></name><name><surname>H&#x000e4;lbig</surname><given-names>TD.</given-names></name><name><surname>Olanow</surname><given-names>CW.</given-names></name></person-group><article-title>Effects of levodopa on cognitive functioning in moderate-to- severe Parkinson's disease (MSPD)</article-title><source><italic>J Neural Transm (Vienna).</italic></source><year>2004</year><volume>111</volume><issue>10-11</issue><fpage>1333</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">15480842</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual-Sedano</surname><given-names>B.</given-names></name><name><surname>Kulisevsky</surname><given-names>J.</given-names></name><name><surname>Barbanoj</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Levodopa and executive performance in Parkinson's disease: a randomized study.</article-title><source><italic>J Int Neuropsychol Soc.</italic></source><year>2008</year><volume>14</volume><issue>5</issue><fpage>832</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">18764978</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Oroz</surname><given-names>MC.</given-names></name><name><surname>Obeso</surname><given-names>JA.</given-names></name><name><surname>Lang</surname><given-names>AE.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.</article-title><source><italic>Brain.</italic></source><year>2005</year><volume>128</volume><issue>10</issue><fpage>2240</fpage><lpage>2249</lpage><pub-id pub-id-type="pmid">15975946</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>FM.</given-names></name><name><surname>Follett</surname><given-names>K.</given-names></name><name><surname>Stern</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.</article-title><source><italic>JAMA.</italic></source><year>2009</year><volume>301</volume><issue>1</issue><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19126811</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R.</given-names></name><name><surname>Stefanova</surname><given-names>E.</given-names></name><name><surname>Barker</surname><given-names>RA.</given-names></name><name><surname>Robbins</surname><given-names>TW.</given-names></name><name><surname>Owen</surname><given-names>AM.</given-names></name></person-group><article-title>Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.</article-title><source><italic>Brain.</italic></source><year>2002</year><volume>125</volume><issue>Pt 3</issue><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">11872615</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotham</surname><given-names>AM.</given-names></name><name><surname>Brown</surname><given-names>RG.</given-names></name><name><surname>Marsden</surname><given-names>CD.</given-names></name></person-group><article-title>'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.</article-title><source><italic>Brain.</italic></source><year>1988</year><volume>111</volume><issue>Pt 2</issue><fpage>299</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">3378138</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>SJ.</given-names></name><name><surname>Dove</surname><given-names>A.</given-names></name><name><surname>Robbins</surname><given-names>TW.</given-names></name><name><surname>Barker</surname><given-names>RA.</given-names></name><name><surname>Owen</surname><given-names>AM.</given-names></name></person-group><article-title>Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.</article-title><source><italic>J Neurosci.</italic></source><year>2003</year><volume>23</volume><issue>15</issue><fpage>6351</fpage><lpage>6356</lpage><pub-id pub-id-type="pmid">12867520</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>NS.</given-names></name><name><surname>Rodnitzky</surname><given-names>RL.</given-names></name><name><surname>Uc</surname><given-names>EY.</given-names></name></person-group><article-title>Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.</article-title><source><italic>Rev Neurosci.</italic></source><year>2013</year><volume>24</volume><issue>3</issue><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">23729617</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>AM.</given-names></name></person-group><article-title>Cognitive fysfunction in Parkinson's disease: The role of frontostriatal circuitry.</article-title><source><italic>Neuroscientist.</italic></source><year>2004</year><volume>10</volume><issue>6</issue><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">15534038</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zgaljardic</surname><given-names>DJ.</given-names></name><name><surname>Borod</surname><given-names>JC.</given-names></name><name><surname>Foldi</surname><given-names>NS.</given-names></name><name><surname>et al</surname></name></person-group><article-title>An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.</article-title><source><italic>J Clin Exp Neuropsychol.</italic></source><year>2006</year><volume>28</volume><issue>7</issue><fpage>1127</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">16840240</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jokinen</surname><given-names>P.</given-names></name><name><surname>Karrasch</surname><given-names>M.</given-names></name><name><surname>Br&#x000fc;ck</surname><given-names>A.</given-names></name><name><surname>Johansson</surname><given-names>J.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name><name><surname>Rinne</surname><given-names>JO.</given-names></name></person-group><article-title>Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction.</article-title><source><italic>J Neurol Sci.</italic></source><year>2013</year><volume>329</volume><issue>1-2</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">23561982</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawamoto</surname><given-names>N.</given-names></name><name><surname>Piccini</surname><given-names>P.</given-names></name><name><surname>Hotton</surname><given-names>G.</given-names></name><name><surname>Pavese</surname><given-names>N.</given-names></name><name><surname>Thielemans</surname><given-names>K.</given-names></name><name><surname>Brooks</surname><given-names>DJ.</given-names></name></person-group><article-title>Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.</article-title><source><italic>Brain.</italic></source><year>2008</year><volume>131</volume><issue>5</issue><fpage>1294</fpage><lpage>1302</lpage><pub-id pub-id-type="pmid">18362097</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balci</surname><given-names>F.</given-names></name><name><surname>Papachristos</surname><given-names>EB.</given-names></name><name><surname>Gallistel</surname><given-names>CR.</given-names></name><name><surname>Brunner</surname><given-names>D.</given-names></name><name><surname>Gibson</surname><given-names>J.</given-names></name><name><surname>Shumyatsky</surname><given-names>GP.</given-names></name></person-group><article-title>Interval timing in genetically modified mice: a simple paradigm.</article-title><source><italic> Genes Brain Behav.</italic></source><year>2008</year><volume>7</volume><issue>3</issue><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">17696995</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakitin</surname><given-names>BC.</given-names></name><name><surname>Gibbon</surname><given-names>J.</given-names></name><name><surname>Penney</surname><given-names>TB.</given-names></name><name><surname>Malapani</surname><given-names>C.</given-names></name><name><surname>Hinton</surname><given-names>SC.</given-names></name><name><surname>Meek</surname><given-names>WH.</given-names></name></person-group><article-title>Scalar expectancy theory and peak-interval timing in humans.</article-title><source><italic>J Exp Psychol Anim Behav Process.</italic></source><year>1998</year><volume>24</volume><issue>1</issue><fpage>15</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9438963</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhusi</surname><given-names>CV.</given-names></name><name><surname>Meek</surname><given-names>WH.</given-names></name></person-group><article-title>Relativity theory and time perception: single or multiple clocks?</article-title><source><italic>PLoS One.</italic></source><year>2009</year><volume>4</volume><issue>7</issue><fpage>e6268</fpage><pub-id pub-id-type="pmid">19623247</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lake</surname><given-names>JI.</given-names></name><name><surname>Meek</surname><given-names>WH.</given-names></name></person-group><article-title>Differential effects of amphetamine and haloperidol on temporal reproduction: dopaminergic regulation of attention and clock speed.</article-title><source><italic>Neuropsychologia.</italic></source><year>2013</year><volume>51</volume><issue>2</issue><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">22982605</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malapani</surname><given-names>C.</given-names></name><name><surname>Rakitin</surname><given-names>B.</given-names></name><name><surname>Levy</surname><given-names>R.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Coupled temporal memories in Parkinson's disease: a dopamine-related dysfunction.</article-title><source><italic>J Cogn Neurosci.</italic></source><year>1998</year><volume>10</volume><issue>3</issue><fpage>316</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">9869707</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maricq</surname><given-names>AV.</given-names></name><name><surname>Church</surname><given-names>RM.</given-names></name></person-group><article-title>The differential effects of haloperidol and methamphetamine on time estimation in the rat.</article-title><source><italic>Psychopharmacology.</italic></source><year>1983</year><volume>79</volume><issue>1</issue><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">6403957</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>KL.</given-names></name><name><surname>Alberico</surname><given-names>SL.</given-names></name><name><surname>Miller</surname><given-names>AD.</given-names></name><name><surname>Narayanan</surname><given-names>NS.</given-names></name></person-group><article-title>Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance.</article-title><source><italic>Neuroscience.</italic></source><year>2013</year><volume>255</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">24120554</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>KL.</given-names></name><name><surname>Chen</surname><given-names>KH.</given-names></name><name><surname>Kingyon</surname><given-names>JR.</given-names></name><name><surname>Cavanagh</surname><given-names>JF.</given-names></name><name><surname>Naryanan</surname><given-names>NS.</given-names></name></person-group><article-title>Medial frontal ~4 Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical dopamine depletion.</article-title><source><italic>J Neurophysiol.</italic></source><year>2015</year><volume>114</volume><issue>2</issue><fpage>1310</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">26133799</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>NS.</given-names></name><name><surname>Land</surname><given-names>BB.</given-names></name><name><surname>Solder</surname><given-names>JE.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name><name><surname>DiLeone</surname><given-names>RJ.</given-names></name></person-group><article-title>Prefrontal D1 dopamine signaling is required for temporal control.</article-title><source><italic>Proc Natl Acad Sci U S A</italic></source><year>2012</year><volume>109</volume><issue>50</issue><fpage>20726</fpage><lpage>20731</lpage><pub-id pub-id-type="pmid">23185016</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>KL.</given-names></name><name><surname>Chen</surname><given-names>K-H.</given-names></name><name><surname>Kingyon</surname><given-names>JR.</given-names></name><name><surname>Cavanagh</surname><given-names>JF.</given-names></name><name><surname>Narayanan</surname><given-names>NS.</given-names></name></person-group><article-title>D1-dependent 4 Hz oscillations and ramping activity in rodent mediaI frontal cortex during interval timing.</article-title><source><italic>J Neurosci</italic></source><year>2014</year><volume>34</volume><fpage>16774</fpage><lpage>16783</lpage><pub-id pub-id-type="pmid">25505330</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehagia</surname><given-names>AA.</given-names></name><name><surname>Murray</surname><given-names>GK.</given-names></name><name><surname>Robbins</surname><given-names>TW.</given-names></name></person-group><article-title>Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation.</article-title><source><italic>Curr Opin Neurobiol.</italic></source><year>2010</year><volume>20</volume><issue>2</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">20167474</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name><name><surname>Mawlawi</surname><given-names>O.</given-names></name><name><surname>Lombardo</surname><given-names>I.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Prefrontal dopamine D1 receptors and working memory in schizophrenia.</article-title><source><italic>J Neurosci.</italic></source><year>2002</year><volume>22</volume><issue>9</issue><fpage>3708</fpage><lpage>3719</lpage><pub-id pub-id-type="pmid">11978847</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunelin</surname><given-names>J.</given-names></name><name><surname>Fecteau</surname><given-names>S.</given-names></name><name><surname>Suaud-Chagny</surname><given-names>MF.</given-names></name></person-group><article-title>Abnormal striatal dopamine transmission in schizophrenia.</article-title><source><italic>Curr Med Chem.</italic></source><year>2013</year><volume>20</volume><issue>3</issue><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">23157632</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corson</surname><given-names>PW.</given-names></name><name><surname>Nopoulos</surname><given-names>P.</given-names></name><name><surname>Miller</surname><given-names>DD.</given-names></name><name><surname>Arndt</surname><given-names>S.</given-names></name><name><surname>Andreasen</surname><given-names>NC.</given-names></name></person-group><article-title>Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.</article-title><source><italic>Am J Psychiatry.</italic></source><year>1999</year><volume>156</volume><issue>8</issue><fpage>1200</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">10450260</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>DR.</given-names></name><name><surname>Berman</surname><given-names>KF.</given-names></name><name><surname>Zee</surname><given-names>RF.</given-names></name></person-group><article-title>Physiologic dysfunction of dorso-lateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence.</article-title><source><italic>Arch Gen Psychiatry.</italic></source><year>1986</year><volume>43</volume><issue>2</issue><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">3947207</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosenick</surname><given-names>L.</given-names></name><name><surname>Marshel</surname><given-names>JH.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>Closed-loop and activity-guided optogenetic control.</article-title><source><italic>Neuron</italic></source><year>2015</year><volume>86</volume><issue>1</issue><fpage>106</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">25856490</pub-id></element-citation></ref></ref-list><glossary><title>Selected abbreviations and acronyms</title><def-list id="DL1"><def-item><term>ChR2</term><def><p>Channelrhodopsin-2</p></def></def-item><def-item><term>DBS</term><def><p>deep brain stimulation</p></def></def-item><def-item><term>MFB</term><def><p>medial forebrain bundle</p></def></def-item><def-item><term>MSN</term><def><p>medium spiny neurons</p></def></def-item><def-item><term>PD</term><def><p>Parkinson disease</p></def></def-item><def-item><term>STN</term><def><p>subthalamic nucleus</p></def></def-item><def-item><term>VTA</term><def><p>ventral tegmental area</p></def></def-item></def-list></glossary></back></article>